• Skip to primary navigation
  • Skip to main content
cropped-KALM-Advisors-Logo-Website-Header-320x120-1.png

Kalm Advisors

  • Show Search
Hide Search
kalm advisors

Your first choice in healthcare consulting.

We’ll guide your business from start-up and launch, through loss of exclusivity.

Scroll down for more information

Let our experience be your guide.

Let our experiences and knowledge pave your path to success. KALM Advisors was founded by Mark Glickman, an innovative leader with 30+ years of experience in the health care business sector. He has been responsible for delivering:

  • Over $10 billion in mergers and acquisitions
  • Multiple in-license deals
  • The largest ever European out-license deal – $900 million with $300 million up front
  • The largest ever Japanese out-license deal – $510 million with $60 million up front
  • 14 product launches
  • Average stock price premiums over 50% to shareholders
  • Leading both small and blockbuster medicines

We devlop Strategy…

Our experience in the healthcare industry is deep and unmatched. We’ll dive into your business goals, to strategize your best path for success.

… and deliver Results

We work with your end goals in mind, while being mindful of your day to day operations. Everything we do provides full transparency and measurable results.


Founded by a results-oriented leader in the space

Founder Mark Glickman brings 30+ years of experience to this venture. Throughout this time, he has excelled in building organizations, transitioning clinical companies into commercial, launching 14 new products, negotiating and closing major licensing deals, negotiating mergers and acquisitions, reconfiguring infrastructures, integrating acquired companies, and generating significant revenue and profit gains – all leading to significant value for shareholders.

Over the past three years, he has established two new commercial entities and successfully launched three products – one directly into the global pandemic, generating significant revenue in 2020. In 2019, he negotiated and closed the two largest out-license deals in pharmaceutical history: a $900 million EU deal with $300 million up front, and a $510 million Japan deal with $60 million up front. These two deals provided the short term cash to support the new commercial initiatives with no additional capital raises.

In senior executive roles, he transformed new entities, or underperforming, inefficient, and declining operations, into high-achieving companies. By spearheading innovative product launches – including orphan launches, directing quality improvements, and ensuring FDA/regulatory compliance – he has led established organizations to up to 700% revenue growth – creating billions of dollars in recognized shareholder premiums.

Mark’s successes resulted from his ability to oversee the entirety of P&L activities, from introducing new products and achieving far greater than forecasted outcomes, to returning failing products to profitability and expanding sales opportunities, to innovating channels and opening up international markets. As a visionary leader, Mark possesses a unique blend of financial skills and commercial experience, with expertise that ranges from development of early-stage companies to expansion of well-established organizations.

He is particularly adept at setting up and building commercial and service organizations, building the distribution and order to cash process, conceiving brand awareness campaigns, leading target market research efforts, and formulating thorough launch plans. In leadership roles, he created value through business development and licensing, mergers and acquisitions, and significant revenue growth.

medicine

Expertise in all that we do.

Our proven track record will grow your business. From business start-up to LOE, we’ll guide your business to execute upon your goals and deliver optimal and measurable results.

We’re currently working within the following areas:


Business Startups

Brand Revitalization

Brand Plans

Talent Acquisition

Mergers & Acquisitions

Brand Strategy

Specialty/orphan

Small molecule

Get in touch.

Let’s talk about the best way to achieve your desired outcomes.


917.275.5881
mark@kalmadvisors.com

  • Linked In

The latest briefings…

Endpoints News – All

WuXi fallout reverberates; Pharma's top R&D spenders; Lilly teams up with Amazon; Historic NASH approval; and more
WuXi fallout reverberates; Pharma's top R&D spenders; Lilly teams up with Amazon; Historic NASH approval; and more
Contineum Therapeutics files for IPO with MS drug in Phase II
Contineum Therapeutics files for IPO with MS drug in Phase II
FDA adcomm backs Carvykti's benefit in earlier patients; Abecma vote to come
Moderna turns the spotlight on long Covid with new initiatives
Bristol Myers scores accelerated approval in more blood cancers for CAR-T therapy Breyanzi
FDA lays out cross-agency efforts on regulating AI in medical products
Biotheus builds on ADC pact with Hansoh; Novartis expands in Singapore; Astellas leaves Cartesian deal
Biotheus builds on ADC pact with Hansoh; Novartis expands in Singapore; Astellas leaves Cartesian deal

More news…

Endpoints News – People

  • FDA’s pediatric adcomm votes to continue surveillance of 21 drugs, three vaccines
  • Federal judge sides with FDA on its mifepristone rules
  • J&J prevails in schizophrenia drug patent spat against Teva
  • Retiring Arvinas CEO reflects on his time leading the PROTAC company
  • CoRegen closes $93M financing round to enter the clinic

Fierce Pharma

RSS Error: A feed could not be found at `https://www.fiercepharma.com/feed`; the status code is `403` and content-type is `text/html; charset=UTF-8`

Seeking Alpha

  • SPMO: Can This Top-Performing Momentum ETF Keep Up The Pace?
  • Has Berkshire Hathaway Lost The Buffett Premium?
  • XRP: Price Nears $2.40 As Garlinghouse Testifies Before U.S. Senate (Technical Analysis)
  • Matson: Underappreciated Compounder With Fortress Balance Sheet
  • OppFi: Remaining Bullish Here, Though A Little More Cautious

Call us today to talk about your business needs.

Kalm Advisors

Copyright © 2025 KALM Advisors · Designed and Maintained by Hello Branding Co · Log in